Taysha Gene Therapies, Inc.
TSHANasdaqHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $9.8M | $8.3M | $15.5M | $2.5M | — | — |
| Operating income | −$110.5M | −$91.5M | −$72.4M | −$162.4M | −$173.3M | −$43.0M |
| Net income | −$109.0M | −$89.3M | −$111.6M | −$166.0M | −$174.5M | −$60.0M |
| Total assets | $343.3M | $160.4M | $172.7M | $126.3M | $214.0M | $258.9M |
| Total liabilities | $96.4M | $88.8M | $97.8M | $125.3M | $118.6M | $7.6M |
| Equity | $246.9M | $71.5M | $74.9M | $949,000 | $95.4M | $251.3M |
| EPS (diluted) | $-0.34 | $-0.36 | $-0.96 | $-3.78 | $-4.64 | — |
| Shares out. | 205.0M | 187.0M | 63.5M | 38.5M | 37.8M | 37.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −1130.6%
- Net margin
- −1115.3%
- Return on equity
- −44.1%
- Return on assets
- −31.7%
- Return on capital (ROCE)
- −34.9%
- Liabilities / assets
- 28.1%
- Debt / equity
- 0.39×
- Book value / share
- $1.20
- Revenue growth (YoY)
- 17.3%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -0.53distress
- Accruals / assets
- −4.6%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 3 warning● 3 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1/2Active Not Recruitingreadout ~2028-11-02Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study)
- Phase 3Recruitingreadout ~2031-06A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study)
- Phase 3Recruitingreadout ~2031-06Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Rtw Investments, LpPassive (13G)May 15, 2026
- Vestal Point Capital, LpPassive (13G)May 15, 2026
- Fmr LlcPassive (13G)Feb 5, 2026
- Blackrock, Inc.Passive (13G)Jan 21, 2026
- Ra Capital Management, L.P.Passive (13G)Nov 14, 2025
- Octagon Capital Advisors LpPassive (13G)Nov 14, 2025
- Morgan StanleyPassive (13G)Aug 6, 2025
- Goldman Sachs Group IncPassive (13G)Jul 3, 2025
- Manning Paul BActivist (13D)Jun 3, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Nagendran SukumarOfficer — President and Head of R&D | Apr 10, 2026 | Option exercise | 19,021 | $1.71 |
| Alam KamranOfficer — CHIEF FINANCIAL OFFICER | Feb 4, 2026 | Sell | 1,655 | $4.52 |
| Nagendran SukumarOfficer — President and Head of R&D | Jan 23, 2026 | Sell | 89,132 | $4.75 |
| Nolan Sean P.Officer — Chief Executive Officer | Jan 23, 2026 | Sell | 136,789 | $4.75 |
| Alam KamranOfficer — CHIEF FINANCIAL OFFICER | Jan 23, 2026 | Sell | 78,968 | $4.75 |
| Alam KamranOfficer — CHIEF FINANCIAL OFFICER | Jan 12, 2026 | Grant | 359,000 | $0.00 |
| Nolan Sean P.Officer — Chief Executive Officer | Jan 12, 2026 | Grant | 1.0M | $0.00 |
| Nagendran SukumarOfficer — President and Head of R&D | Jan 12, 2026 | Option exercise | 111,324 | $0.70 |
| Nagendran SukumarOfficer — President and Head of R&D | Nov 28, 2025 | Option exercise | 70,172 | $0.70 |
| Nagendran SukumarOfficer — President and Head of R&D | Sep 10, 2025 | Option exercise | 41,150 | $0.70 |
| Nagendran SukumarOfficer — President and Head of R&D | Aug 21, 2025 | Sell | 57,054 | $2.85 |
| Alam KamranOfficer — CHIEF FINANCIAL OFFICER | Aug 21, 2025 | Sell | 54,491 | $2.85 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 36.7M | 15.1 | -8.4% |
| Apr 30, 2026 | 40.1M | 14.0 | +2.9% |
| Apr 15, 2026 | 38.9M | 14.2 | -7.9% |
| Mar 31, 2026 | 42.3M | 13.1 | -8.9% |
| Mar 13, 2026 | 46.4M | 15.9 | -6.6% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 6, 2026
- Results of operationsMar 19, 2026
- Entered a material agreement · Results of operationsNov 4, 2025
- Other material eventOct 16, 2025
- Other material eventOct 9, 2025
- Other material eventOct 2, 2025
- Results of operationsAug 12, 2025
- Amended charter or bylaws · Shareholder voteJun 3, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13G/AMay 15, 2026
- 10-QMay 6, 2026
- 8-KMay 6, 2026
- ARSApr 22, 2026
- DEFA14AApr 22, 2026
- DEF 14AApr 22, 2026
- 4Apr 13, 2026
- 144Apr 10, 2026
- 10-KMar 19, 2026
- 8-KMar 19, 2026
- 144Feb 27, 2026
- SCHEDULE 13GFeb 17, 2026
- SCHEDULE 13G/AFeb 17, 2026
- 4Feb 6, 2026
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.